智通财经APP讯,和铂医药-B(02142)发布公告,公司将于2025年10月17日至10月21日在德国柏林举办的2025年欧洲肿瘤内科学会(ESMO)年会上,公布其新一代全人源仅重链抗CTLA-4抗体普鲁苏拜单抗(HBM4003)联合替雷利珠单抗治疗微卫星稳定型(MSS)转移性结直肠癌(mCRC)的II期临床数据。
普鲁苏拜单抗(HBM4003)是开发自HCAb Harbour Mice®平台的新一代全人源仅重链抗CTLA-4抗体,是全球首个进入临床阶段的全人源仅重链抗体。相较于传统的抗CTLA-4抗体,普鲁苏拜单抗具有显著增加的Treg细胞清除和优化的药代动力学等独特及良好的特性,有助于提高安全性。此外,通过增强抗体依赖的细胞毒性(ADCC),普鲁苏拜单抗提升了选择性清除瘤内Treg细胞的潜力,有望克服现有 CTLA-4疗法的疗效和毒性瓶颈。公司已开展普鲁苏拜单抗治疗多种实体瘤的全球开发计划,并采用了普鲁苏拜单抗的适应性治疗设计。在针对晚期实体瘤的单药治疗以及联合PD-1抑制剂治疗黑色素瘤、结直肠癌、神经内分泌癌及肝细胞癌的临床试验中,均观察到了积极的疗效及安全性数据。
更多港股重磅资讯,下载智通财经app
更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.